Objective:

To evaluate the cost savings of dose rounding for trastuzumab deruxtecan in China and compare the safety profiles of different rounding strategies among patients.

Approach:

Key Findings:

• Dose rounding down led to a cost saving of CNY 897,840.
• Dose rounding up avoided 4,368.3 mg of drug waste.
• Dose deviations ranged from 0.10% to 9.97%, within the 10% acceptable limit.
• The incidence and severity of adverse events were comparable across groups, with no statistically significant differences.

Interpretation:

Dose rounding of trastuzumab deruxtecan to the nearest full vial within a 10% deviation range can significantly reduce drug waste and pharmacy costs without compromising safety.

Limitations:

• The study is retrospective and may not capture all variables influencing outcomes.
• Findings are based on a limited sample size and specific patient population, which may affect generalizability.

Conclusion:

The study provides preliminary evidence on the cost savings associated with dose rounding in Chinese patients, pending validation in larger studies.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.